2023 annual financial data
Inhibikase Therapeutics 2023 Net margin
Direct answer
Net margin was -7,304.75%.
Operating income was -20.09M USD and net income was -19.03M USD.
Operating cash flow was -18.09M USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 260,500 USD
- Operating income
- -20.09M USD
- Net income
- -19.03M USD
- Operating cash flow
- -18.09M USD
Explore related company data
View all 2023 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Operating marginView Operating cash flow marginView all Inhibikase Therapeutics financial years